<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d1618962-0dd9-4186-a383-74e823f5f7a2"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ZEPZELCA safely and effectively.  See full prescribing information for ZEPZELCA.<br/>
      <br/>
      <content styleCode="bold">ZEPZELCA<sup>®</sup> (lurbinectedin) for injection, for intravenous use</content>
      <br/>Initial U.S. Approval: 2020</title>
   <effectiveTime value="20250430"/>
   <setId root="632bb50c-3bcb-4c85-9056-fc33410550ae"/>
   <versionNumber value="6"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="135926363" root="1.3.6.1.4.1.519.1"/>
            <name>Jazz Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="896650210" root="1.3.6.1.4.1.519.1"/>
                  <name>Jazz Pharmaceuticals Ireland Limited</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="344276063" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Oncology GmbH</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68727-712" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68727-712" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68727-712" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68727-712" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="464884501" root="1.3.6.1.4.1.519.1"/>
                        <name>Pharma Mar, SA</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68727-712" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="098908572" root="1.3.6.1.4.1.519.1"/>
                        <name>AndersonBrecon Inc (Specialty Pharma Center SPC)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68727-712" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68727-712" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="462006581" root="1.3.6.1.4.1.519.1"/>
                        <name>GP Pharm SA</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68727-712" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="896650210" root="1.3.6.1.4.1.519.1"/>
                        <name>Jazz Pharmaceuticals Ireland Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68727-712" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="99f21e80-60f5-49f9-8fca-d6dc1206a562"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20200615"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68727-712" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZEPZELCA</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Lurbinectedin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value=".5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2CN60TN6ZS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LURBINECTEDIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2CN60TN6ZS" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LURBINECTEDIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2.76"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="33X04XA5AT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTIC ACID, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value=".64"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="8"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68727-712-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200615"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213702" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200615"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>white to off-white powder</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_2666f6d0-de16-4a5d-bc8a-41721843e7bb">
               <id root="63d6d358-78e6-475e-b727-7c80b8e8f7a4"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <paragraph>Dosage and Administration (<linkHtml href="#ID_8e932319-867b-4428-8a8c-23c35c94d405">2.3</linkHtml>, <linkHtml href="#ID_a9dfadca-e3ab-4f73-b36f-14778c306d35">2.4</linkHtml>)                                                                                     04/2025<br/>Use in Specific Populations (<linkHtml href="#ID_6a949702-81a2-4a80-a5ee-0eb8f380c94e">8.6</linkHtml>)                                                                                           04/2025</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_fc062c69-e9b5-4051-8f90-1f7539342868">
               <id root="483176d2-5222-4abd-90e3-6fe295a1221d"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>ZEPZELCA is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.</paragraph>
                  <paragraph>This indication is approved under accelerated approval based on overall response rate and duration of response <content styleCode="italics">[see</content>
                     <content styleCode="italics">
                        <linkHtml href="#ID_8a528a70-2b1f-427e-8c4a-5f90759a8262"> Clinical Studies (14)</linkHtml>
                     </content>
                     <content styleCode="italics">]</content>. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ZEPZELCA is an alkylating drug indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. <content styleCode="underline">(</content>
                           <linkHtml href="#ID_fc062c69-e9b5-4051-8f90-1f7539342868">1</linkHtml>
                           <content styleCode="underline">)</content>
                        </paragraph>
                        <paragraph>This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). <content styleCode="underline">(</content>
                           <linkHtml href="#ID_fc062c69-e9b5-4051-8f90-1f7539342868">1</linkHtml>
                           <content styleCode="underline">)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_971034c5-2de7-4064-a029-43da04f3a7ff">
               <id root="9cacf7cc-6c50-46b1-8807-40fd144c4d80"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Recommended Dosage</content>: 3.2 mg/m<sup>2</sup> every 21 days until disease progression or unacceptable toxicity. (<linkHtml href="#ID_61615414-8531-4a40-82c2-22f1b54a9593">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Administer ZEPZELCA as an intravenous infusion over 60 minutes. (<linkHtml href="#ID_61615414-8531-4a40-82c2-22f1b54a9593">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Consider premedication with corticosteroids and serotonin antagonists for antiemetic prophylaxis. (<linkHtml href="#ID_54c923a0-830b-481f-9d5a-1e91ba986071">2.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Moderate Hepatic Impairment</content>: Recommended dosage is 1.6 mg/m<sup>2</sup> every 21 days until disease progression or unacceptable toxicity. (<linkHtml href="#ID_a9dfadca-e3ab-4f73-b36f-14778c306d35">2.4</linkHtml>, <linkHtml href="#ID_6a949702-81a2-4a80-a5ee-0eb8f380c94e">8.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Severe Hepatic Impairment</content>: Avoid use of ZEPZELCA. If use cannot be avoided, the recommended dosage is 1.6 mg/m<sup>2</sup> by intravenous infusion every 21 days until disease progression or unacceptable toxicity. (<linkHtml href="#ID_a9dfadca-e3ab-4f73-b36f-14778c306d35">2.4</linkHtml>, <linkHtml href="#ID_6a949702-81a2-4a80-a5ee-0eb8f380c94e">8.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_61615414-8531-4a40-82c2-22f1b54a9593">
                     <id root="fa83e246-50a2-4b22-943c-6e3d154cdb15"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage </title>
                     <text>
                        <paragraph>The recommended dosage of ZEPZELCA is 3.2 mg/m<sup>2</sup> by intravenous infusion over 60 minutes every 21 days until disease progression or unacceptable toxicity.</paragraph>
                        <paragraph>Initiate treatment with ZEPZELCA only if absolute neutrophil count (ANC) is at least 1,500 cells/mm<sup>3</sup> and platelet count is at least 100,000/mm<sup>3</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20200615"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_dba1b0e4-701d-4dab-8056-4c775a3ba307">
                     <id root="d57ea0f9-4c56-4593-b329-4547f4c83230"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage Modifications for Adverse Reactions </title>
                     <text>
                        <paragraph>The recommended dose reductions for adverse reactions are listed in Table 1. </paragraph>
                        <paragraph>Permanently discontinue ZEPZELCA in patients who are unable to tolerate 2 mg/m<sup>2</sup> or require a dose delay greater than two weeks.</paragraph>
                        <table styleCode="Noautorules" width="100%">
                           <caption>Table 1: Dose Reduction for ZEPZELCA for Adverse Reactions</caption>
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dose Reduction</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Total Dose</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">First</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Second</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>2.6 mg/m<sup>2 </sup>every 21 days</paragraph>
                                    <paragraph>2 mg/m<sup>2</sup> every 21 days</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Dosage modifications for ZEPZELCA for adverse reactions are presented in Table 2.</paragraph>
                        <table styleCode="Noautorules" width="100%">
                           <caption>Table 2: Dosage Modifications for ZEPZELCA for Adverse Reactions</caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>a</sup>  National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>b</sup>  Patients with isolated Grade 4 neutropenia (neutrophil count less than 500 cells/mm<sup>3</sup>) may receive G-CSF prophylaxis rather than undergo lurbinectedin dose reduction.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Severity<sup>a</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dosage Modification</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Neutropenia<sup>b</sup>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">[see <linkHtml href="#ID_c5e29efc-c0d4-4f0d-a3fb-1ec020b30f6d">Warnings and Precautions (5.1)</linkHtml>]</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Grade 4</paragraph>
                                    <paragraph>    or</paragraph>
                                    <paragraph>Any grade febrile neutropenia</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>Withhold ZEPZELCA until Grade ≤ 1</item>
                                       <item>
                                          <caption>•</caption>Resume ZEPZELCA at a reduced dose</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Thrombocytopenia</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">[see <linkHtml href="#ID_c5e29efc-c0d4-4f0d-a3fb-1ec020b30f6d">Warnings and Precautions (5.1)</linkHtml>]</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Grade 3 with bleeding</paragraph>
                                    <paragraph>    or</paragraph>
                                    <paragraph>Grade 4</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>Withhold ZEPZELCA until platelet ≥ 100,000/mm<sup>3</sup>
                                       </item>
                                       <item>
                                          <caption>•</caption>Resume ZEPZELCA at reduced dose</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Hepatotoxicity</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">[see <linkHtml href="#ID_a70011e7-3b8c-423b-be89-c6de1762b729">Warnings and Precautions (5.2)</linkHtml>]</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Grade 2</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>Withhold ZEPZELCA until Grade ≤ 1</item>
                                       <item>
                                          <caption>•</caption>Resume ZEPZELCA at same dose</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Grade ≥ 3</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>Withhold ZEPZELCA until Grade ≤ 1</item>
                                       <item>
                                          <caption>•</caption>Resume ZEPZELCA at reduced dose or permanently discontinue</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Rhabdomyolysis</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">[see <linkHtml href="#ID_0c2f1634-222c-4e9c-80e9-42dd73172f75">Warnings and Precautions (5.4)</linkHtml>]</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Grade 2</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>Withhold ZEPZELCA until Grade ≤ 1</item>
                                       <item>
                                          <caption>•</caption>Resume ZEPZELCA at same dose</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Grade ≥ 3</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>Permanently discontinue ZEPZELCA.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Other Adverse Reactions</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">[see <linkHtml href="#ID_dd8357ba-85a3-4114-bdb0-80b71f170d7f">Postmarketing (6.2)</linkHtml>]</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Grade 2</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>Withhold ZEPZELCA until Grade ≤ 1</item>
                                       <item>
                                          <caption>•</caption>Resume ZEPZELCA at same dose</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Grade ≥ 3</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>Withhold ZEPZELCA until Grade ≤ 1</item>
                                       <item>
                                          <caption>•</caption>Resume ZEPZELCA at reduced dose or permanently discontinue</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8e932319-867b-4428-8a8c-23c35c94d405">
                     <id root="03b98565-eff9-4d0d-b063-61f6410220ee"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.3 Dosage Modifications for Use with Strong and Moderate CYP3A Inhibitors</content>
                        <content styleCode="xmChange"/>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Avoid coadministration of ZEPZELCA with strong or moderate CYP3A inhibitors. If coadministration of ZEPZELCA with a strong or moderate CYP3A inhibitor cannot be avoided, reduce the dose of ZEPZELCA by 50%</content>
                           <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_c4670268-529c-490a-882b-420f5ba0a464">Drug Interactions (7.1)</linkHtml>
                           </content>
                           <content styleCode="italics"> and <linkHtml href="#ID_2bbb21ca-c88b-4ffd-8486-86ec42c5b8ce">Clinical Pharmacology (12.3)</linkHtml>]</content>. <content styleCode="xmChange">After discontinuation of a strong or moderate CYP3A inhibitor for 5 half-lives of the inhibitor, increase the ZEPZELCA dose to the dose used before starting the inhibitor</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_233faaf5-61f2-4577-a00e-0a7e62950bc8">
                     <id root="fcc7388d-5830-404b-8e94-45fab916d80b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.4 Dosage Modifications for Patients with Severe and Moderate Hepatic Impairment</content>
                        <content styleCode="xmChange"/>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Avoid administration of ZEPZELCA in patients with severe hepatic impairment (total bilirubin &gt; 3 × Upper Limit of Normal (ULN)). If administration of ZEPZELCA cannot be avoided, the recommended dosage is 1.6 mg/m2 by intravenous infusion over 60 minutes every 21 days until disease progression or unacceptable toxicity</content>
                           <content styleCode="italics">[see <linkHtml href="#ID_6a949702-81a2-4a80-a5ee-0eb8f380c94e">Specific populations (8.6) </linkHtml>and <linkHtml href="#ID_2bbb21ca-c88b-4ffd-8486-86ec42c5b8ce">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In patients with moderate hepatic impairment (total bilirubin &gt; 1.5 to ≤ 3 × ULN and any AST), the recommended dosage of ZEPZELCA is 1.6 mg/m<sup>2</sup> by intravenous infusion over 60 minutes every 21 days until disease progression or unacceptable toxicity.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a9dfadca-e3ab-4f73-b36f-14778c306d35">
                     <id root="1c0443cd-639b-4765-b7b1-4ca933f3d433"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Premedication</title>
                     <text>
                        <paragraph>Consider administering the following pre-infusion medications for antiemetic prophylaxis <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_ee1a41f7-b2e9-494a-89c3-df5e32032be3"> Adverse Reactions (6.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Corticosteroids (dexamethasone 8 mg intravenously or equivalent)</item>
                           <item>
                              <caption>•</caption>Serotonin antagonists (ondansetron 8 mg intravenously or equivalent)</item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_54c923a0-830b-481f-9d5a-1e91ba986071">
                     <id root="cfb8e2ea-9ce1-4e9b-ad5c-317340254441"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Preparation, Administration and Storage </title>
                     <text>
                        <paragraph>ZEPZELCA is a hazardous drug. Follow applicable special handling and disposal procedures<sup>1</sup>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Preparation</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Inject 8 mL of Sterile Water for Injection USP into the vial, yielding a solution containing 0.5 mg/mL lurbinectedin. Shake the vial until complete dissolution. </item>
                           <item>
                              <caption>•</caption>Visually inspect the solution for particulate matter and discoloration. The reconstituted solution is a clear, colorless or slightly yellowish solution, essentially free of visible particles.</item>
                           <item>
                              <caption>•</caption>Calculate the required volume of reconstituted solution as follows:</item>
                           <item>
                              <caption> </caption>
                              <renderMultiMedia ID="id743222524" referencedObject="ID_461e09cc-937f-467f-828a-a6fa3a18565e"/>
                           </item>
                           <item>
                              <caption>•</caption>For administration through a central venous line, withdraw the appropriate amount of reconstituted solution from the vial and add to an infusion container containing at least 100 mL of diluent (0.9% Sodium Chloride Injection USP or 5% Dextrose Injection USP).</item>
                           <item>
                              <caption>•</caption>For administration through a peripheral venous line, withdraw the appropriate amount of reconstituted solution from the vial and add to an infusion container containing at least 250 mL of diluent (0.9% Sodium Chloride Injection USP or 5% Dextrose Injection USP).</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Administration</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If particulate matter is observed, do not administer.</item>
                           <item>
                              <caption>•</caption>ZEPZELCA can be administered with or without an in-line filter. If infusion lines containing in-line filters are utilized for administration of ZEPZELCA, polyethersulfone (PES) in-line filters with pore sizes of 0.22 micron are recommended. <list listType="unordered">
                                 <item>
                                    <caption>o</caption>Do not use in-line nylon membrane filters when the reconstituted ZEPZELCA solution is diluted using 0.9% Sodium Chloride Injection, USP. Adsorption of ZEPZELCA to the Nylon membrane filters has been observed when 0.9% Sodium Chloride Injection, USP is used as the diluent.</item>
                              </list>
                           </item>
                        </list>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Compatibility with other intravenous administration materials and the diluted ZEPZELCA solution has been demonstrated in the following materials: <list listType="unordered">
                                 <item>
                                    <caption>o</caption>Polyolefin containers (polyethylene, polypropylene and mixtures). </item>
                                 <item>
                                    <caption>o</caption>Polyvinyl Chloride (PVC) (non-DEHP-containing), polyurethane and polyolefin infusion sets (polyethylene, polypropylene and polybutadiene). </item>
                                 <item>
                                    <caption>o</caption>Implantable venous access systems with titanium and plastic resin ports and with polyurethane or silicone intravenous catheters. </item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>Do not co-administer ZEPZELCA and other intravenous drugs concurrently within the same intravenous line.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Storage of Infusion Solution</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>If not used immediately after reconstitution or dilution, the ZEPZELCA solution can be stored prior to administration for up to 24 hours following reconstitution, including infusion time, at either room temperature/ ambient light or under refrigeration at 2ºC to 8ºC (36ºF to 46ºF) conditions.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                     <component>
                        <observationMedia ID="ID_461e09cc-937f-467f-828a-a6fa3a18565e">
                           <text>volume calculation</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="volume.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_252b835b-96df-4390-a142-148523acf805">
               <id root="79959d18-c383-4573-ab42-5cdac12e8726"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>For injection: 4 mg of lurbinectedin as a sterile, preservative-free, white to off-white lyophilized powder in a single-dose vial for reconstitution prior to intravenous infusion.</paragraph>
               </text>
               <effectiveTime value="20220414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For injection: 4 mg lyophilized powder in a single-dose vial. (<linkHtml href="#ID_252b835b-96df-4390-a142-148523acf805">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_220ca5cc-16d2-4c60-b491-280c9385240d">
               <id root="ad692571-785c-41a3-8553-ce376db89da7"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20220414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#ID_220ca5cc-16d2-4c60-b491-280c9385240d">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_866df38d-b23f-4509-83ea-18295d976a25">
               <id root="808098df-c590-4c23-9d01-415525a2be24"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20230728"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Myelosuppression</content>: Monitor blood counts prior to each administration. Initiate treatment with ZEPZELCA only if baseline neutrophil count is ≥ 1,500 cells/mm<sup>3</sup> and platelet count is ≥ 100,000/mm<sup>3</sup>. Withhold, reduce the dose, or permanently discontinue ZEPZELCA based on severity. (<linkHtml href="#ID_dba1b0e4-701d-4dab-8056-4c775a3ba307">2.2</linkHtml>, <linkHtml href="#ID_c5e29efc-c0d4-4f0d-a3fb-1ec020b30f6d">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Hepatotoxicity</content>: Monitor liver function tests prior to initiating ZEPZELCA, periodically during treatment and as clinically indicated. Withhold, reduce the dose, or permanently discontinue ZEPZELCA based on severity. (<linkHtml href="#ID_dba1b0e4-701d-4dab-8056-4c775a3ba307">2.2</linkHtml>, <linkHtml href="#ID_a70011e7-3b8c-423b-be89-c6de1762b729">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Extravasation Resulting in Tissue Necrosis</content>: Consider use of a central venous catheter to reduce the risk of extravasation. Monitor patients for signs and symptoms of extravasation during the ZEPZELCA infusion. If extravasation occurs, immediately discontinue the infusion, remove the infusion catheter, and monitor for signs and symptoms of tissue necrosis. (<linkHtml href="#ID_63b6df4b-fd05-43fe-947a-41b2954a7a71">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Rhabdomyolysis</content>: Monitor creatine phosphokinase (CPK) prior to initiating ZEPZELCA and periodically during treatment as clinically indicated. Withhold, reduce the dose, or permanently discontinue ZEPZELCA based on severity. (<linkHtml href="#ID_0c2f1634-222c-4e9c-80e9-42dd73172f75">5.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. Advise females and males of reproductive potential of the potential risk to a fetus and to use an effective method of contraception. (<linkHtml href="#ID_8188008d-db55-48ce-b483-a2a08a6bc695">5.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_c5e29efc-c0d4-4f0d-a3fb-1ec020b30f6d">
                     <id root="c4f6b283-0497-4434-a3e4-b2d756e1b2cd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Myelosuppression </title>
                     <text>
                        <paragraph>ZEPZELCA can cause myelosuppression. </paragraph>
                        <paragraph>In clinical studies of 554 patients with advanced solid tumors receiving ZEPZELCA <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_6b368b22-ec0c-42df-b812-6ea06e080cae">Adverse Reactions (6.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>, Grade 3 or 4 neutropenia occurred in 41% of patients, with a median time to onset of 15 days and a median duration of 7 days. Febrile neutropenia occurred in 7% of patients. Sepsis occurred in 2% of patients and was fatal in 1% (all cases occurred in patients with solid tumors other than SCLC).  Grade 3 or 4 thrombocytopenia occurred in 10%, with a median time to onset of 10 days and a median duration of 7 days. Grade 3 or 4 anemia occurred in 17% of patients.</paragraph>
                        <paragraph>Administer ZEPZELCA only to patients with baseline neutrophil count of at least 1,500 cells/mm<sup>3</sup> and platelet count of at least 100,000/mm<sup>3</sup>. Monitor blood counts including neutrophil count and platelet count prior to each administration. For neutrophil count less than 500 cells/mm<sup>3</sup> or any value less than lower limit of normal, the use of G-CSF is recommended. Withhold, reduce the dose, or permanently discontinue ZEPZELCA based on severity <content styleCode="italics">[see <linkHtml href="#ID_dba1b0e4-701d-4dab-8056-4c775a3ba307">Dosage and Administration (2.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220414"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a70011e7-3b8c-423b-be89-c6de1762b729">
                     <id root="e5413b35-48b6-46d6-a32e-e29c8b9e8cf9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hepatotoxicity </title>
                     <text>
                        <paragraph>ZEPZELCA can cause hepatotoxicity.</paragraph>
                        <paragraph>In clinical studies of 554 patients with advanced solid tumors receiving ZEPZELCA <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_6b368b22-ec0c-42df-b812-6ea06e080cae"> Adverse Reactions (6.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>, Grade 3 elevations of ALT and AST were observed in 6% and 3% of patients, respectively, and Grade 4 elevations of ALT and AST were observed in 0.4% and 0.5% of patients, respectively. The median time to onset of Grade ≥ 3 elevation in transaminases was 8 days (range: 3 to 49), with a median duration of 7 days.</paragraph>
                        <paragraph>Monitor liver function tests prior to initiating ZEPZELCA and periodically during treatment as clinically indicated. Withhold, reduce the dose, or permanently discontinue ZEPZELCA based on severity <content styleCode="italics">[see <linkHtml href="#ID_dba1b0e4-701d-4dab-8056-4c775a3ba307">Dosage and Administration (2.2)</linkHtml>]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230728"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_63b6df4b-fd05-43fe-947a-41b2954a7a71">
                     <id root="ee963989-194e-4710-9d4b-2c2d549b9f16"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Extravasation Resulting in Tissue Necrosis </title>
                     <text>
                        <paragraph>Extravasation of ZEPZELCA resulting in skin and soft tissue injury, including necrosis requiring debridement, can occur. Consider use of a central venous catheter to reduce the risk of extravasation, particularly in patients with limited venous access. Monitor patients for signs and symptoms of extravasation during the ZEPZELCA infusion. If extravasation occurs, immediately discontinue the infusion, remove the infusion catheter, and monitor for signs and symptoms of tissue necrosis. The time to onset of necrosis after extravasation may vary.</paragraph>
                        <paragraph>Administer supportive care and consult with an appropriate medical specialist as needed for signs and symptoms of extravasation. Administer subsequent infusions at a site that was not affected by extravasation.</paragraph>
                     </text>
                     <effectiveTime value="20220414"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0c2f1634-222c-4e9c-80e9-42dd73172f75">
                     <id root="d0a87cb9-7e56-4011-934a-cf69e3766036"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Rhabdomyolysis </title>
                     <text>
                        <paragraph>Rhabdomyolysis has been reported in patients treated with ZEPZELCA. Monitor creatine phosphokinase (CPK) prior to initiating ZEPZELCA and periodically during treatment as clinically indicated. Withhold or reduce the dose based on severity <content styleCode="italics">[see <linkHtml href="#ID_dba1b0e4-701d-4dab-8056-4c775a3ba307">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220414"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8188008d-db55-48ce-b483-a2a08a6bc695">
                     <id root="aa2f02df-9acf-4a25-94e1-726c1c20fa75"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Embryo-Fetal Toxicity </title>
                     <text>
                        <paragraph>Based on animal data and its mechanism of action ZEPZELCA can cause fetal harm when administered to a pregnant woman. Intravenous administration of a single dose of lurbinectedin (approximately 0.2 times the 3.2 mg/m<sup>2</sup> clinical dose) to pregnant animals during the period of organogenesis caused 100% embryolethality in rats. Advise pregnant women of the potential risk to a fetus. Advise female patients of reproductive potential to use effective contraception during treatment with ZEPZELCA and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ZEPZELCA and for 4 months after the last dose <content styleCode="italics">[see <linkHtml href="#ID_8b8064aa-0a13-4d26-98f9-1cb3d4d31284">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#ID_9fd0d396-576b-4997-a956-ede4813a6355">8.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230728"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_ee1a41f7-b2e9-494a-89c3-df5e32032be3">
               <id root="b449d659-d42e-45ac-8cf3-7510e78ce8ac"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Myelosuppression <content styleCode="italics">[see <linkHtml href="#ID_c5e29efc-c0d4-4f0d-a3fb-1ec020b30f6d">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#ID_a70011e7-3b8c-423b-be89-c6de1762b729">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Extravasation Resulting in Tissue Necrosis <content styleCode="italics">[see </content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_63b6df4b-fd05-43fe-947a-41b2954a7a71">Warnings and Precautions (5.3)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>
                        <caption>•</caption>Rhabdomyolysis <content styleCode="italics">[see <linkHtml href="#ID_0c2f1634-222c-4e9c-80e9-42dd73172f75">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions, including laboratory abnormalities, (≥20%) are leukopenia, lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, thrombocytopenia, nausea, decreased appetite, musculoskeletal pain, decreased albumin, constipation, dyspnea, decreased sodium, increased aspartate aminotransferase, vomiting, cough, decreased magnesium and diarrhea. (<linkHtml href="#ID_6b368b22-ec0c-42df-b812-6ea06e080cae">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Jazz Pharmaceuticals, Inc. at 1-800-520-5568</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_6b368b22-ec0c-42df-b812-6ea06e080cae">
                     <id root="3ca1c977-d474-431d-92b6-d73fbe0de0c8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to ZEPZELCA as a single agent at a dose of 3.2 mg/m<sup>2</sup> intravenously every 21 days in 554 patients with advanced solid tumors. Among 554 patients who received ZEPZELCA, including 105 patients with small cell lung cancer (SCLC) in PM1183-B-005-14 (Study B-005), 24% were exposed for 6 months or longer and 5% were exposed for greater than one year.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Small Cell Lung Cancer (SCLC)</content>
                        </paragraph>
                        <paragraph>The safety of ZEPZELCA was evaluated in a cohort of 105 patients with previously treated SCLC in Study B-005 <content styleCode="italics">[see <linkHtml href="#ID_8a528a70-2b1f-427e-8c4a-5f90759a8262">Clinical Studies (14)</linkHtml>]</content>. Patients received ZEPZELCA 3.2 mg/m<sup>2</sup> intravenously every 21 days. All patients in this study received a pre-specified anti-emetic regimen consisting of a corticosteroid and serotonin antagonist. Patients could receive G-CSF for secondary prophylaxis (i.e., after patients had an initial decrease in WBC), but not primary prophylaxis. Among patients who received ZEPZELCA, 29% were exposed for 6 months or longer and 6% were exposed for greater than one year. </paragraph>
                        <paragraph>Serious adverse reactions occurred in 34% of patients who received ZEPZELCA. Serious adverse reactions in ≥ 3% of patients included pneumonia, febrile neutropenia, neutropenia, respiratory tract infection, anemia, dyspnea, and thrombocytopenia. </paragraph>
                        <paragraph>Permanent discontinuation due to an adverse reaction occurred in two patients (1.9%) who received ZEPZELCA. Adverse reactions resulting in permanent discontinuation in ≥ 1% of patients who received ZEPZELCA, which included peripheral neuropathy and myelosuppression.</paragraph>
                        <paragraph>Dosage interruptions due to an adverse reaction occurred in 30.5% of patients who received ZEPZELCA. Adverse reactions requiring dosage interruption in ≥ 3% of patients who received ZEPZELCA included neutropenia, and hypoalbuminemia.</paragraph>
                        <paragraph>Dose reductions due to an adverse reaction occurred in 25% of patients who received ZEPZELCA. Adverse reactions requiring dosage reductions in ≥ 3% of patients who received ZEPZELCA included neutropenia, febrile neutropenia and fatigue.</paragraph>
                        <paragraph>The most common adverse reactions, including laboratory abnormalities, (≥ 20%) were leukopenia, lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, thrombocytopenia, nausea, decreased appetite, musculoskeletal pain, decreased albumin, constipation, dyspnea, decreased sodium, increased aspartate aminotransferase, vomiting, cough, decreased magnesium and diarrhea.</paragraph>
                        <paragraph>Table 3 summarizes the adverse reactions in the SCLC cohort of Study B-005.</paragraph>
                        <table styleCode="Noautorules" width="100%">
                           <caption>Table 3: Adverse Reactions (≥ 10%) in Patients with SCLC Who Received ZEPZELCA in Study B-005</caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>a</sup>  Graded per NCI CTCAE 4.0.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>b</sup>  No grade 5 adverse reactions were reported.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>c</sup>  Includes abdominal pain, abdominal pain upper and abdominal discomfort.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>d</sup>  Includes musculoskeletal pain, back pain, arthralgia, pain in extremity, musculoskeletal chest pain, neck pain, bone pain and myalgia.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>e</sup>  Includes cough and productive cough.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>f</sup>  Includes upper respiratory tract infection, viral upper respiratory tract infection, respiratory tract infection and bronchitis.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>g</sup>  Includes pneumonia and lung infection.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>h</sup>  Includes neuropathy peripheral, neuralgia, paresthesia, peripheral sensory neuropathy, hypoesthesia, and hyperesthesia.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">ZEPZELCA</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=105)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">All Grades</content>
                                       <sup>a,b</sup>
                                       <content styleCode="bold"> (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Grades 3-4 (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">General disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Fatigue</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>77</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pyrexia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>13</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Chest pain</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Gastrointestinal disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>37</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Constipation</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>31</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>22</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Diarrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>20</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Abdominal pain<sup>c</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Musculoskeletal pain<sup>d</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>33</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Metabolism and nutrition disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Decreased appetite</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>33</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Dyspnea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>31</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Cough<sup>e</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>20</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Infections and infestations</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Respiratory tract infection<sup>f</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pneumonia<sup>g</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Nervous system disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Peripheral neuropathy<sup>h</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant adverse reactions in &lt; 10% of patients who received ZEPZELCA include dysgeusia, febrile neutropenia and pneumonitis.</paragraph>
                        <paragraph>Table 4 summarizes the laboratory abnormalities in Study B-005.</paragraph>
                        <table styleCode="Noautorules" width="100%">
                           <caption>Table 4: Select Laboratory Abnormalities (≥ 20%) Worsening from Baseline in Patients with SCLC Who Received ZEPZELCA in Study B-005</caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>a</sup>  The denominator used to calculate the rate varied from 95 to 105 based on the number of patients with a baseline value and at least one post-treatment value.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>b</sup>  Graded per NCI CTCAE 4.0.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Laboratory Abnormality</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">ZEPZELCA<sup>a</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=105)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">All Grades<sup>b</sup> (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Grades 3-4 (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Hematology</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Decreased leukocytes</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>79</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>29</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Decreased lymphocytes</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>79</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>43</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Decreased hemoglobin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>74</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>10</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Decreased neutrophils</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>71</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>46</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Decreased platelets</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>37</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Chemistry</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Increased creatinine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>69</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Increased alanine aminotransferase</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>66</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Increased glucose</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>52</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Decreased albumin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>32</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Decreased sodium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>31</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Increased aspartate aminotransferase</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>26</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Decreased magnesium</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>22</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_dd8357ba-85a3-4114-bdb0-80b71f170d7f">
                     <id root="e2fc0e7c-8d02-4bbe-a350-7459cd9c0e2f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of ZEPZELCA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">General disorders and administration site conditions:</content> Extravasation including tissue necrosis requiring debridement. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders:</content> Rhabdomyolysis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and nutrition disorders:</content> Tumor lysis syndrome.</paragraph>
                     </text>
                     <effectiveTime value="20220414"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5f886a4f-02de-46a2-aa14-59a60c1c0240">
               <id root="a8f9c12a-3d1c-4da5-8b89-bccbfef58535"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Effect of Other Drugs on ZEPZELCA</content>: Avoid coadministration. (<linkHtml href="#ID_c4670268-529c-490a-882b-420f5ba0a464">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_c4670268-529c-490a-882b-420f5ba0a464">
                     <id root="e0e3b300-a1dc-46bf-8416-f56beb1dcc32"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of Other Drugs on ZEPZELCA </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Strong and Moderate CYP3A Inhibitors</content>
                        </paragraph>
                        <paragraph>Coadministration of ZEPZELCA with a strong or a moderate CYP3A inhibitor increases lurbinectedin systemic exposure <content styleCode="italics">[see <linkHtml href="#ID_2bbb21ca-c88b-4ffd-8486-86ec42c5b8ce">Clinical Pharmacology (12.3)</linkHtml>],</content> which may increase the incidence and severity of adverse reactions to ZEPZELCA.</paragraph>
                        <paragraph>Avoid grapefruit and Seville oranges during ZEPZELCA treatment, as these contain strong or moderate inhibitors of CYP3A.</paragraph>
                        <paragraph>Avoid coadministration of ZEPZELCA with strong or moderate CYP3A inhibitors. If coadministration cannot be avoided, reduce the dose of ZEPZELCA <content styleCode="italics">[see <linkHtml href="#ID_8e932319-867b-4428-8a8c-23c35c94d405">Dosage and Administration (2.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Strong CYP3A Inducers</content>
                        </paragraph>
                        <paragraph>Avoid coadministration of ZEPZELCA with strong CYP3A inducers. Coadministration of ZEPZELCA with a strong CYP3A inducer may decrease lurbinectedin systemic exposure, which may decrease the efficacy of ZEPZELCA <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_2bbb21ca-c88b-4ffd-8486-86ec42c5b8ce">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f6cff50a-a3cb-4a6b-9787-e663e9411362">
               <id root="163036ce-4ca8-4d49-8254-62dc6fc2daa9"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>: Advise not to breastfeed. (<linkHtml href="#ID_2917b79f-90b2-439f-abae-94b16207efdf">8.2</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hepatic Impairment</content>: Avoid use of ZEPZELCA in patients with severe hepatic impairment. In patients with moderate hepatic impairment, reduce dose. (<linkHtml href="#ID_233faaf5-61f2-4577-a00e-0a7e62950bc8">2.4</linkHtml>, <linkHtml href="#ID_6a949702-81a2-4a80-a5ee-0eb8f380c94e">8.6</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_8b8064aa-0a13-4d26-98f9-1cb3d4d31284">
                     <id root="f82397bb-b6bd-4a85-9d1f-fd1f8abb8b17"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Based on animal data and its mechanism of action <content styleCode="italics">[see <linkHtml href="#ID_49166bb6-1a1d-4e8f-9dab-c0b1fd6dbef7">Clinical Pharmacology (12.1)</linkHtml>]</content>, ZEPZELCA can cause fetal harm when administered to a pregnant woman. There are no available data to inform the risk of ZEPZELCA use in pregnant women. Intravenous administration of a single lurbinectedin dose (approximately 0.2 times the 3.2 mg/m<sup>2</sup> clinical dose) to pregnant rats during the period of organogenesis caused embryolethality <content styleCode="italics">(see Data)</content>. </paragraph>
                        <paragraph>Advise pregnant women of the potential risk to a fetus. </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>In a reproductive toxicity study, administration of a single lurbinectedin dose of 0.6 mg/m<sup>2</sup> (approximately 0.2 times of the human dose of 3.2 mg/m<sup>2</sup>) to pregnant rats on Gestation Day 10 resulted in 100% post-implantation loss.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2917b79f-90b2-439f-abae-94b16207efdf">
                     <id root="6f38e1ed-fbc7-4a1c-a744-1f2385d5d74b"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of lurbinectedin in human milk or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions from ZEPZELCA in breastfed children, advise women not to breastfeed during treatment with ZEPZELCA and for 2 weeks after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9fd0d396-576b-4997-a956-ede4813a6355">
                     <id root="1357a4c5-be6f-4798-8a51-50c9e21aabb2"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential </title>
                     <text>
                        <paragraph>ZEPZELCA can cause embryolethality at doses lower than the human dose of 3.2 mg/m<sup>2 </sup>
                           <content styleCode="italics">[see <linkHtml href="#ID_8b8064aa-0a13-4d26-98f9-1cb3d4d31284">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Verify the pregnancy status of females of reproductive potential prior to initiating ZEPZELCA.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Advise female patients of reproductive potential to use effective contraception during treatment with ZEPZELCA and for 6 months after the last dose.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Advise males with a female sexual partner of reproductive potential to use effective contraception during treatment with ZEPZELCA and for 4 months after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20230728"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7eea28cd-708b-4fab-b851-6b7804ab7fa7">
                     <id root="d895f8eb-8c19-4cc6-acd1-27224cff2078"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness of ZEPZELCA in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20200615"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3783a681-db49-4879-8166-d6bb258084a9">
                     <id root="6218d404-490c-4db6-93c8-314507163044"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Of the 105 patients with SCLC administered ZEPZELCA in clinical studies, 37 (35%) patients were 65 years of age and older, while 9 (9%) patients were 75 years of age and older. No overall difference in effectiveness was observed between patients aged 65 and older and younger patients.</paragraph>
                        <paragraph>There was a higher incidence of serious adverse reactions in patients ≥ 65 years of age than in patients &lt; 65 years of age (49% vs. 26%, respectively). The serious adverse reactions most frequently reported in patients ≥ 65 years of age were related to myelosuppression and consisted of febrile neutropenia (11%), neutropenia (11%), thrombocytopenia (8%), and anemia (8%) <content styleCode="italics">[see</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_6b368b22-ec0c-42df-b812-6ea06e080cae"> Adverse Reactions (6.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20211001"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6a949702-81a2-4a80-a5ee-0eb8f380c94e">
                     <id root="32b20b7d-efcb-4f07-9abb-edb612df5a52"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment </title>
                     <text>
                        <paragraph>Avoid administration of ZEPZELCA in patients with severe hepatic impairment (total bilirubin &gt; 3 × ULN). If administration of ZEPZELCA cannot be avoided, reduce the dose <content styleCode="italics">[see <linkHtml href="#ID_233faaf5-61f2-4577-a00e-0a7e62950bc8">Dosage and Administration (2.4)</linkHtml>]</content>. Monitor for increased adverse reactions in patients with severe hepatic impairment.</paragraph>
                        <paragraph>Reduce the dose of ZEPZELCA in patients with moderate hepatic impairment (total bilirubin &gt; 1.5 to 3 × ULN and any AST) <content styleCode="italics">[see <linkHtml href="#ID_233faaf5-61f2-4577-a00e-0a7e62950bc8">Dosage and Administration (2.4)</linkHtml>]</content>. Monitor for increased adverse reactions in patients with moderate hepatic impairment.</paragraph>
                        <paragraph>No dose adjustment of ZEPZELCA is recommended for patients with mild hepatic impairment (total bilirubin ≤ ULN and AST &gt; ULN, or total bilirubin 1 to ≤ 1.5 × ULN and any AST) <content styleCode="italics">[see <linkHtml href="#ID_2bbb21ca-c88b-4ffd-8486-86ec42c5b8ce" title="Clinical Pharmacology (12.3)">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f179fc08-848c-4ef4-bf57-534ff9260905">
               <id root="171b54a9-f02f-48a8-ad0a-a54e75c73c28"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>ZEPZELCA is an alkylating drug.  The chemical name of ZEPZELCA (lurbinectedin) is (1’R,6R,6aR,7R,13S,14S,16R)-8,14-dihydroxy-6’,9-dimethoxy-4,10,23-trimethyl-19-oxo-2’,3’,4’,6,7,9’,12,13,14,16-decahydro-6aH-spiro[7,13-azano-6,16-(epithiopropanooxymethano) [1,3]dioxolo[7,8]isoquinolino[3,2-b][3]benzazocine-20,1’-pyrido[3,4-b]indol]-5-yl acetate.</paragraph>
                  <paragraph>The molecular formula is C<sub>41</sub>H<sub>44</sub>N<sub>4</sub>O<sub>10</sub>S. The molecular weight is 784.87g/mol, and the chemical structure is:</paragraph>
                  <renderMultiMedia ID="id391857231" referencedObject="ID_4c9e5452-afb4-40c7-836e-e807efd96391"/>
                  <paragraph>ZEPZELCA for injection 4 mg is supplied as a lyophilized powder in a single-dose vial for reconstitution for intravenous use. The ZEPZELCA lyophilized formulation is comprised of 4 mg lurbinectedin, sucrose (800 mg), lactic acid (22.1 mg), and sodium hydroxide (5.1 mg). Before use, the lyophilizate is reconstituted by addition of 8 mL Sterile Water for Injection USP, yielding a solution containing 0.5 mg/mL lurbinectedin (the calculated concentration is 0.47 mg/mL based on the final volume of 8.5 mL).</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="ID_4c9e5452-afb4-40c7-836e-e807efd96391">
                     <text>chemical-structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="chemical-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5a3b2111-2874-4720-a258-56061f00a507">
               <id root="b60b2831-8616-4152-aa37-eead70908398"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="ID_49166bb6-1a1d-4e8f-9dab-c0b1fd6dbef7">
                     <id root="a0b21f2d-0ab4-4418-a280-724ec50e0292"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Lurbinectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. Adduct formation triggers a cascade of events that can affect the subsequent activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death. </paragraph>
                        <paragraph>Lurbinectedin inhibited human monocyte activity in vitro and reduced macrophage infiltration in implanted tumors in mice.</paragraph>
                     </text>
                     <effectiveTime value="20200615"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a430bff4-888e-4789-8000-0612a9c84a5a">
                     <id root="aeaa26ab-470a-4241-a0b8-57f34629cc18"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>Lurbinectedin exposure-response relationships and the pharmacodynamic time-course for efficacy have not been fully characterized.</paragraph>
                        <paragraph>Increased incidence of Grade 4 neutropenia and Grade ≥ 3 thrombocytopenia were observed with increased lurbinectedin exposure.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>No large mean increase in QTc (i.e., &gt; 20 ms) was detected at the recommended dose of 3.2 mg/m<sup>2</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20230728"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2bbb21ca-c88b-4ffd-8486-86ec42c5b8ce">
                     <id root="3ea6a021-919e-4617-b07a-4a726a2110a2"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Following the approved recommended dosage, geometric mean (%CV) of plasma C<sub>max</sub> and AUC<sub>0-inf</sub>, were 107 µg/L (79%) and 551 µg•h/L (94%), respectively. No accumulation of lurbinectedin in plasma is observed upon administrations every 3 weeks. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution </content>
                        </paragraph>
                        <paragraph>The volume of distribution of lurbinectedin at steady state is 504 L (39%). Plasma protein binding is approximately 99%, to both albumin and α-1-acid glycoprotein.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The terminal half-life of lurbinectedin is 51 hours. Total plasma clearance of lurbinectedin is 11 L/h (50%).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Lurbinectedin is metabolized by CYP3A in vitro.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>After a single dose of radiolabeled lurbinectedin, 89% of the radioactivity was recovered in feces (&lt; 0.2% unchanged) and 6% in urine (1% unchanged).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>No clinically significant differences in the pharmacokinetics of lurbinectedin were identified based on age (18-85 years), sex, body weight (39-154 kg), or mild to moderate renal impairment (CLcr 30 to 89 mL/min). The effects of severe renal impairment (CLcr &lt; 30 mL/min) on the pharmacokinetics of lurbinectedin have not been studied.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="italics">
                                 <content styleCode="underline">Hepatic Impairment</content>
                              </content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">No clinically significant differences in the pharmacokinetics of lurbinectedin were identified for patients with mild hepatic impairment (total bilirubin ≤ ULN and AST &gt; ULN or total bilirubin 1 to 1.5 × ULN and any AST) compared to that of patients with normal hepatic function.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">No clinically significant differences in the pharmacokinetics of lurbinectedin were identified for patients with moderate hepatic impairment (total bilirubin &gt; 1.5 to 3 × ULN and any AST) who received a lurbinectedin dose of 1.6 mg/m<sup>2</sup> compared to that of patients with mild hepatic impairment who received a dose of 3.2 mg/m<sup>2</sup>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">No clinically significant differences in the pharmacokinetics of lurbinectedin were identified for patients with severe hepatic impairment (total bilirubin &gt; 3 × ULN) who received a lurbinectedin dose of 1.6 mg/m<sup>2</sup> compared to that of patients with mild hepatic impairment who received a dose of 3.2 mg/m<sup>2</sup>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Studies and Model-Informed Approaches</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effects of CYP3A Inhibitors on Lurbinectedin </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="italics">Strong CYP3A inhibitors:</content> Coadministration of itraconazole (200 mg once daily) increased the systemic exposure (AUC) of total lurbinectedin by 2.7-fold and unbound lurbinectedin by 2.4‑fold. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="italics">Moderate CYP3A inhibitors:</content> Coadministration of verapamil (80 mg every 8 hours) and erythromycin (500 mg every 6 hours) is predicted to increase lurbinectedin AUC by 2.3-fold and 2.1-fold, respectively.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="italics">Weak CYP3A inhibitors:</content> Coadministration of fluvoxamine (150 mg every 12 hours) is predicted to increase lurbinectedin AUC by 1.3-fold.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effects of CYP3A Inducers on Lurbinectedin</content>
                        </paragraph>
                        <paragraph>Coadministration of bosentan (a moderate CYP3A inducer) decreased systemic exposure (AUC) of total lurbinectedin by 20% and unbound lurbinectedin by 19%. These changes are not considered clinically relevant.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cytochrome P450 (CYP) Enzymes:</content> Lurbinectedin is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. </paragraph>
                        <paragraph>Lurbinectedin is not an inducer of CYP1A2 or CYP3A4. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Transporter Systems:</content> Lurbinectedin is a substrate of MDR1, but is not a substrate of OATB1P1, OATP1B3, OCT1, or MATE1. </paragraph>
                        <paragraph>Lurbinectedin inhibits MDR1, OATP1B1, OATP1B3, and OCT1 but not BCRP, BSEP, MATE1, OAT1, OAT3, or OCT2.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c574d1fb-f46c-4f1b-b4cb-2acf3c63f769">
               <id root="d73b5a70-bbe1-4576-a81c-f668ea5406d3"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="ID_c61649da-25d0-4664-aa9f-8730a1349cae">
                     <id root="22e7e99a-7d2e-474c-9961-f7f1aec4b333"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>Carcinogenicity testing of lurbinectedin has not been performed. Lurbinectedin is genotoxic to mammalian cells in the presence and absence of metabolic activation. Lurbinectedin was not mutagenic in vitro in a bacterial reverse mutation (Ames) assay.</paragraph>
                        <paragraph>Fertility studies with lurbinectedin were not performed. There were no findings in reproductive organs in general toxicology studies in rats, dogs, or monkeys; however, the highest doses and exposures in these studies were all at levels lower than those at the human dose of 3.2 mg/m<sup>2</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8a528a70-2b1f-427e-8c4a-5f90759a8262">
               <id root="1f2b2302-2f3d-4580-abb9-fcd3d1229c80"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>PM1183-B-005-14 (Study B-005; NCT02454972) is a multicenter, open-label, multi-cohort trial evaluating ZEPZELCA as a single agent in patients with advanced or metastatic solid tumors. A cohort of patients with small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy received ZEPZELCA 3.2 mg/m<sup>2</sup> by intravenous infusion every 21 days (one cycle). Patients received a median of 4 cycles of ZEPZELCA (range 1 to 24 cycles). The trial excluded patients with central nervous system (CNS) involvement, grade ≥ 3 dyspnea, daily intermittent oxygen requirement, hepatitis or cirrhosis, and immunocompromised patients. Tumor assessments were conducted every 6 weeks for the first 18 weeks and every 9 weeks thereafter. The major efficacy outcome measure was confirmed investigator-assessed overall response rate (ORR). Additional efficacy outcome measures included duration of response (DoR), and an Independent Review Committee (IRC) assessed ORR using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).</paragraph>
                  <paragraph>A total of 105 patients with SCLC who progressed on or after platinum-based chemotherapy were enrolled. The median age was 60 years (range: 40 to 83) with 65% of patients &lt; 65 years and 35% of patients ≥ 65 years, and 60% were male. The majority (75%) of the patients were White, 1% were Asian, 1% were Black and 23% were not reported. Baseline ECOG performance status was 0 or 1 in 92% of patients, and 92% were former/current smokers. All patients received at least one line of platinum-based chemotherapy (range 1-2 lines), and prior radiotherapy had been administered to 71% of patients. Eight patients (8%) had prior immunotherapy in addition to platinum-based chemotherapy. Sixty patients (57%) had platinum-sensitive SCLC, defined as recurrence or progression ≥ 90 days after the last dose of platinum-containing therapy (chemotherapy free interval [CTFI] ≥ 90 days). The remaining 45 patients had platinum-resistant SCLC, defined as recurrence or progression &lt; 90 days after the last dose of platinum-containing therapy (CTFI &lt; 90 days).</paragraph>
                  <paragraph>Table 5 summarizes investigator-assessed and independent review committee assessed key efficacy measures in all patients and in platinum-resistant and platinum-sensitive subgroups.</paragraph>
                  <table styleCode="Noautorules" width="100%">
                     <caption>Table 5: Efficacy Results in SCLC Cohort of Study B-005</caption>
                     <col width="25%"/>
                     <col width="25%"/>
                     <col width="25%"/>
                     <col width="25%"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="4" valign="top">CI: confidence interval, CTFI: chemotherapy free interval.</td>
                        </tr>
                        <tr>
                           <td align="left" colspan="4" valign="top">
                              <sup>a</sup>  Confirmed overall response rate.</td>
                        </tr>
                        <tr>
                           <td align="left" colspan="4" valign="top">
                              <sup>b</sup>  Based on observed duration of response.</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                              <paragraph>
                                 <content styleCode="bold">Investigator Assessed Response<sup>a</sup>
                                 </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">ZEPZELCA<br/>All Patients<br/>(n=105)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">ZEPZELCA<br/>CTFI &lt; 90 days<br/>(n=45)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">ZEPZELCA<br/>CTFI ≥ 90 days<br/>(n=60)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Overall Response Rate</content> (95% CI)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>35% (26%, 45%)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>22% (11%, 37%)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>45% (32%, 58%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Complete response</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>0%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>0%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>0%</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Partial response</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>35%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>22%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>45%</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Duration of Response</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Median in months (95% CI)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>5.3 (4.1, 6.4)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>4.7 (2.6, 5.6)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>6.2 (3.5, 7.3)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     % with ≥ 6 months<sup>b</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>35%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>10%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>44%</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Independent Review Committee Assessed Response<sup>a</sup>
                                 </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">All Patients<br/>(n=105)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">CTFI &lt; 90 days<br/>(n=45)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">CTFI ≥ 90 days<br/>(n=60)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Overall Response Rate</content> (95% CI)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>30% (22%, 40%)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>13% (5%, 27%)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>43% (31%, 57%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Complete response</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>0%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>0%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>0%</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Partial response</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>30%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>13%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>43%</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Duration of Response</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>     Median in months (95% CI)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>5.1 (4.9, 6.4)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>4.8 (2.4, 5.3)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>5.3 (4.9, 7.0)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>     % with ≥ 6 months<sup>b</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>25%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>0%</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>31%</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="ID_1e5ec5d6-86b5-4a1d-943f-397e8dc61dd6">
               <id root="adea4098-513f-42ad-a7f2-7757be09afa2"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES </title>
               <text>
                  <paragraph>1. "OSHA Hazardous Drugs." OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html</paragraph>
               </text>
               <effectiveTime value="20200615"/>
            </section>
         </component>
         <component>
            <section ID="ID_2773c863-0344-42ac-8039-63e880206f8a">
               <id root="4b9bd4e6-98cb-4478-bc4f-f37511ba1660"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph>ZEPZELCA (lurbinectedin) for injection is supplied as a sterile, preservative-free, white to off-white lyophilized powder in a single-dose clear glass vial. Each carton (NDC 68727-712-01) contains 4 mg in one single-dose vial.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store refrigerated at 2°C to 8°C (36°F to 46°F).</paragraph>
                  <paragraph>ZEPZELCA is a hazardous drug. Follow applicable special handling and disposal procedures<sup>1</sup>.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="ID_75b294be-e441-4282-a4e5-8da796ea7030">
               <id root="52ec9ccf-08e6-4890-aaf2-365a2e8f94d8"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Myelosuppression</content>
                  </paragraph>
                  <paragraph>Advise patients to immediately contact their healthcare provider for fever, other signs of infection, unusual bruising, bleeding, tiredness or pallor <content styleCode="italics">[see<linkHtml href="#ID_c5e29efc-c0d4-4f0d-a3fb-1ec020b30f6d"> Warnings and Precautions (5.1)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity</content>
                  </paragraph>
                  <paragraph>Advise patients to contact their healthcare provider immediately for signs and symptoms suggestive of hepatotoxicity <content styleCode="italics">[see<linkHtml href="#ID_a70011e7-3b8c-423b-be89-c6de1762b729"> Warnings and Precautions (5.2)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Extravasation Resulting in Tissue Necrosis</content>
                  </paragraph>
                  <paragraph>Advise patients to contact their healthcare provider immediately for signs and symptoms of extravasation. The time to onset of necrosis after extravasation may vary <content styleCode="italics">[see <linkHtml href="#ID_63b6df4b-fd05-43fe-947a-41b2954a7a71">Warnings and Precautions (5.3)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Rhabdomyolysis </content>
                  </paragraph>
                  <paragraph>Advise patients to contact their healthcare provider immediately for signs and symptoms of rhabdomyolysis <content styleCode="italics">[see <linkHtml href="#ID_0c2f1634-222c-4e9c-80e9-42dd73172f75">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                  <paragraph>Embryo-Fetal Toxicity</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see <linkHtml href="#ID_8188008d-db55-48ce-b483-a2a08a6bc695">Warnings and Precautions (5.5)</linkHtml>
                        </content> and <content styleCode="italics">
                           <linkHtml href="#ID_8b8064aa-0a13-4d26-98f9-1cb3d4d31284">Use in Specific Populations (8.1)</linkHtml>]</content>.</item>
                     <item>
                        <caption>•</caption>Advise females of reproductive potential to use effective contraception during treatment with ZEPZELCA and for 6 months after the last dose <content styleCode="italics">[see<linkHtml href="#ID_9fd0d396-576b-4997-a956-ede4813a6355"> Use in Specific Populations (8.3)</linkHtml>]</content>.</item>
                     <item>
                        <caption>•</caption>Advise males with female partners of reproductive potential to use effective contraception during treatment with ZEPZELCA and for 4 months after the last dose <content styleCode="italics">[see </content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_9fd0d396-576b-4997-a956-ede4813a6355">Use in Specific Populations (8.3)</linkHtml>]</content>.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with ZEPZELCA and for at least 2 weeks after the last dose <content styleCode="italics">[see<linkHtml href="#ID_2917b79f-90b2-439f-abae-94b16207efdf"> Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Advise patients to inform their healthcare providers of all concomitant medications, herbal and dietary supplements. Advise patients to avoid grapefruit products and Seville oranges during treatment with ZEPZELCA <content styleCode="italics">[see <linkHtml href="#ID_c4670268-529c-490a-882b-420f5ba0a464">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <br/>
                     <br/>Distributed by:<br/>Jazz Pharmaceuticals, Inc.<br/>Palo Alto, CA 94304<br/>
                  </paragraph>
                  <paragraph>Under license from Pharma Mar, S.A.<br/>
                     <br/>
                  </paragraph>
                  <paragraph>Protected by U.S. Patent No. 7,763,615</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="ID_95736532-792a-4ec8-953e-1e145f0ffe3a">
               <id root="2286b1ba-7032-4af5-9079-9fd021bb2915"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>Patient Package Insert </title>
               <text>
                  <table styleCode="Noautorules" width="100%">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">PATIENT INFORMATION</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">ZEPZELCA<sup>®</sup> (zep zel' kah)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(lurbinectedin)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">for injection</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is ZEPZELCA?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>ZEPZELCA is used to treat adults with a kind of lung cancer called small cell lung cancer (SCLC). ZEPZELCA may be used when your lung cancer:<list listType="unordered">
                                       <item>
                                          <caption>o</caption>has spread to other parts of the body (metastatic), <content styleCode="bold">and</content>
                                       </item>
                                       <item>
                                          <caption>o</caption>you have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working.</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>It is not known if ZEPZELCA is safe and effective in children.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before receiving ZEPZELCA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>have liver or kidney problems.</item>
                                 <item>
                                    <caption>•</caption>are pregnant or plan to become pregnant. ZEPZELCA can harm your unborn baby.<br/>
                                    <content styleCode="bold">Females who are able to become pregnant:</content>
                                    <list listType="unordered">
                                       <item>
                                          <caption>o</caption>Your healthcare provider should do a pregnancy test before you start treatment with ZEPZELCA.</item>
                                       <item>
                                          <caption>o</caption>You should use effective birth control (contraception) during treatment with and for 6 months after your last dose of ZEPZELCA.</item>
                                       <item>
                                          <caption>o</caption>Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with ZEPZELCA.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Males with female partners who are able to become pregnant</content> should use effective birth control during treatment with and for 4 months after your last dose of ZEPZELCA.</item>
                                 <item>
                                    <caption>•</caption>are breastfeeding or plan to breastfeed. It is not known if ZEPZELCA passes into your breastmilk. Do not breastfeed during treatment with ZEPZELCA and for 2 weeks after your last dose of ZEPZELCA. Talk to your healthcare provider about the best way to feed your baby during treatment with ZEPZELCA.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how ZEPZELCA works. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How will I receive ZEPZELCA?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>ZEPZELCA is given by an intravenous (IV) infusion into a vein over 60 minutes. </item>
                                 <item>
                                    <caption>•</caption>ZEPZELCA is usually given every 21 days. </item>
                                 <item>
                                    <caption>•</caption>Before each treatment with ZEPZELCA, you may receive medicines to help prevent nausea and vomiting or make it less severe. </item>
                                 <item>
                                    <caption>•</caption>Your healthcare provider will decide how long you will continue treatment with ZEPZELCA. </item>
                                 <item>
                                    <caption>•</caption>Your healthcare provider may do certain tests during your treatment with ZEPZELCA to check you for side effects, and to see how well you respond to the treatment. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What should I avoid while using ZEPZELCA?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Avoid eating or drinking grapefruit, Seville oranges, or products that contain grapefruit juice and Seville oranges during treatment with ZEPZELCA.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of ZEPZELCA?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">ZEPZELCA can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Low blood cell counts.</content> Low blood counts including low neutrophil counts (neutropenia) and low platelet counts (thrombocytopenia) are common with ZEPZELCA, and can also be severe. Some people with low white blood cell counts may get fever, or an infection throughout the body (sepsis), that can cause death. Your healthcare provider should do blood tests before you receive each treatment with ZEPZELCA to check your blood cell counts.<br/>
                                    <content styleCode="bold">Tell your healthcare provider right away if you develop:</content>
                                 </item>
                              </list>
                              <paragraph>             ○    fever or any other signs of infection</paragraph>
                              <paragraph>             ○    unusual bruising or bleeding</paragraph>
                              <paragraph>             ○    tiredness</paragraph>
                              <paragraph>             ○    pale colored skin</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Liver problems.</content> Increased liver function tests are common with ZEPZELCA and can also be severe. Your healthcare provider should do blood tests to check your liver function before you start and during treatment with ZEPZELCA.<br/>
                                    <content styleCode="bold">Tell your healthcare provider right away if you develop symptoms of liver problems including:</content>
                                 </item>
                              </list>
                              <paragraph>             ○    loss of appetite</paragraph>
                              <paragraph>             ○    nausea or vomiting</paragraph>
                              <paragraph>             ○    pain on the right side of your stomach-area (abdomen)</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Leakage of ZEPZELCA out of your vein during the infusion.</content> If ZEPZELCA leaks into the tissues around your infusion site, it can cause damage and death of tissue cells around the infusion site. You may need to have surgery to remove any dead tissue. Tell your healthcare provider right away if you see any ZEPZELCA leaking out of your vein or around the catheter during your infusion, or if you notice any redness, swelling, itching or discomfort at the infusion site at any time. </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Severe muscle problems (rhabdomyolysis).</content> Tell your healthcare provider if you have severe muscle pain or weakness. </item>
                              </list>
                              <paragraph>Your healthcare provider may temporarily stop treatment, lower your dose, or permanently stop ZEPZELCA if you develop serious side effects during treatment with ZEPZELCA.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of ZEPZELCA include:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>tiredness</item>
                                 <item>
                                    <caption>•</caption>low white and red blood cell counts</item>
                                 <item>
                                    <caption>•</caption>increased kidney function blood test (creatinine)</item>
                                 <item>
                                    <caption>•</caption>increased liver function blood tests</item>
                                 <item>
                                    <caption>•</caption>increased blood sugar (glucose)</item>
                                 <item>
                                    <caption>•</caption>nausea</item>
                                 <item>
                                    <caption>•</caption>decreased appetite</item>
                                 <item>
                                    <caption>•</caption>muscle and joint (musculoskeletal) pain</item>
                                 <item>
                                    <caption>•</caption>low level of albumin in the blood</item>
                                 <item>
                                    <caption>•</caption>constipation</item>
                                 <item>
                                    <caption>•</caption>trouble breathing</item>
                                 <item>
                                    <caption>•</caption>low levels of sodium and magnesium in the blood</item>
                                 <item>
                                    <caption>•</caption>vomiting</item>
                                 <item>
                                    <caption>•</caption>cough</item>
                                 <item>
                                    <caption>•</caption>diarrhea</item>
                              </list>
                              <paragraph>These are not all of the possible side effects of ZEPZELCA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of ZEPZELCA.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about ZEPZELCA that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in ZEPZELCA?<br/>Active ingredient:</content> lurbinectedin<br/>
                                 <content styleCode="bold">Inactive ingredients:</content> sucrose, lactic acid and sodium hydroxide.<br/>
                              </paragraph>
                              <paragraph>Distributed by: Jazz Pharmaceuticals, Inc.</paragraph>
                              <paragraph>Palo Alto, CA 94304</paragraph>
                              <paragraph>Under license from Pharma Mar, S.A.</paragraph>
                              <paragraph>ZEPZELCA is a registered trademark of Pharma Mar, S.A.</paragraph>
                              <paragraph>For more information, go to <linkHtml href="http://www.ZEPZELCA.com">www.ZEPZELCA.com</linkHtml> or call 1-800-520-5568.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.                                                                                                                                       Revised: 07/2023</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="ID_c01278fa-10d3-4490-9e26-3420e3c64909">
               <id root="3eb48c07-f63b-4de5-a70e-0cc4032a50d4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <paragraph>
                     <renderMultiMedia ID="id171768512" referencedObject="ID_14c8cf15-3393-4008-90bf-a47df6ef7d3b"/>
                     <br/>Carton:</paragraph>
                  <paragraph>NDC 68727-712-01<br/>ZEPZELCA<br/>(lurbinectedin)<br/>for injection<br/>4 mg per vial<br/>FOR INTRAVENOUS INFUSION ONLY <br/>Reconstitute before further dilution.<br/>Each single-dose vial contains 4 mg of lurbinectedin<br/>as a sterile lyophilized powder<br/>Rx Only<br/>Single-dose vial<br/>Discard unused portion.<br/>Caution: Cytotoxic agent</paragraph>
               </text>
               <effectiveTime value="20210622"/>
               <component>
                  <observationMedia ID="ID_14c8cf15-3393-4008-90bf-a47df6ef7d3b">
                     <text>carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4871d009-00aa-4ce6-886f-13abdc258bc9">
               <id root="9210cd33-7246-4800-b174-10fbf55949e2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel </title>
               <text>
                  <paragraph>
                     <renderMultiMedia ID="id-2095925408" referencedObject="C78D936B-03F5-4563-97E4-6425D4B01EA8"/>
                     <br/>Vial:</paragraph>
                  <paragraph>NDC 68727-712-01<br/>ZEPZELCA<br/>(lurbinectedin)<br/>for injection<br/>4 mg per vial<br/>FOR INTRAVENOUS INFUSION ONLY <br/>Single-Dose Vial.<br/>Discard unused portion.</paragraph>
               </text>
               <effectiveTime value="20210622"/>
               <component>
                  <observationMedia ID="C78D936B-03F5-4563-97E4-6425D4B01EA8">
                     <text>vial</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="vial.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>